World’s largest dedicated cell and-gene-therapy manufacturing facility opens

10 Apr 2018

First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.

Lonza today is opening the world’s largest dedicated cell-and-gene-therapy facility, which was built in anticipation of the rising demand from developers of cell and gene therapies – the next era in medicine – and with the mission of enabling them to deliver these types of treatments to patients around the world more quickly and efficiently.

World’s largest dedicated cell and-gene-therapy manufacturing facility opens
Ribbon cutting.

During a grand opening ceremony today in Pearland, TX (USA), Lonza executives and industry leaders will unveil the 300,000-sq-ft (27,870 m2) facility and its offerings, highlighting its state-of-the-art, fully integrated, everything-under-one-roof access to some of the world's most innovative cell-and-gene-therapy manufacturing technologies.

"Lonza Houston will serve as a center of excellence for cell-and-gene-therapy process development from concept through preclinical, clinical and commercialization, all the way to the patient," says Andreas Weiler, Business Unit head for Emerging Technologies at Lonza Pharma & Biotech. "This facility has the potential to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases, under one roof. It will set a new standard in biopharmaceutical manufacturing and stand as one of four centers of excellence in cell and gene therapy in the only global network spanning three continents."

He adds: "Outstanding teams of top experts from around the world are gathered here and are empowered to elaborate on innovative concepts, develop and optimize complex processes, and seamlessly deliver cell and gene therapies that adhere to the industry’s cGMP standards."

The Lonza Houston Center of Excellence is already operational and manufacturing for several customers. This facility is recruiting employees and will have more than 200 full-time staff including scientists, engineers, MBAs and biotechnology professionals by the end of 2018 and continue to recruit high-value positions as market demand increases.

“Lonza is committed to the evolution and cultivation of a diverse medical and life-science community in the Greater Houston area for many years to come," says Marc Funk, Lonza Pharma & Biotech Chief Operating Officer. “The site is well positioned to meet the demands of the growing cell-and-gene-therapy field. Combining this leading-edge facility with our unmatched experience and expertise in cell and gene therapy will allow us to provide a key advantage to biopharmaceutical companies and academic researchers and ultimately to the patients they serve.”

Read More

Related tags

Market News

Related news

TraceLink unveils Product Information Manager for its digital information sharing platform

TraceLink unveils Product Information Manager for its digital information sharing platform

12 Jul 2018

Product Information Manager addresses a broad range of use cases, beginning with saleable returns.

Read more 
Stability studies trends

Stability studies trends

10 Jul 2018

Dr Ramesh Jagadeesan, Sr. Director - Analytical Development at Recipharm, speaks to CPhI Online on the trends and challenges involved with conducting stability studies for firms that supply to multiple countries, and the advantages of using a contracto...

Read more 
Recipharm launches standalone serialisation service

Recipharm launches standalone serialisation service

5 Jul 2018

Company will be able to add 2D codes, human-readable text and tamper evidence to pre-packed medicines using existing equipment across its facilities.

Read more 
CPhI Worldwide opens entries for 15th Annual Pharma Awards

CPhI Worldwide opens entries for 15th Annual Pharma Awards

5 Jul 2018

Winners will be announced live at the Gala Ceremony in Madrid with over 500 of Pharma’s top executives.

Read more 
Catalent to acquire Juniper Pharmaceuticals

Catalent to acquire Juniper Pharmaceuticals

5 Jul 2018

$133 million deal adds European Early Development Center of Excellence to global network.

Read more 
Insights in lyophilization science

Insights in lyophilization science

4 Jul 2018

The latest developments in process development, nucleation control, scale-up of freeze drying cycles and development in lyophilization technology.

Read more 
Bosch to sell its packaging business

Bosch to sell its packaging business

4 Jul 2018

Packaging technology is not a core Bosch business.

Read more 
Plasticell leads gene therapy manufacturing consortium

Plasticell leads gene therapy manufacturing consortium

3 Jul 2018

Consortium to develop advanced technologies for the manufacturing of ex vivo gene therapies.

Read more 
Forté Pharma strengthens its leadership in weight control in France

Forté Pharma strengthens its leadership in weight control in France

1 Jul 2018

Company consolidated as one of the leading laboratories in weight control thanks to the development of its existing range and new launches.

Read more 
I Holland woos exhibition visitors with new tabletting technologies

I Holland woos exhibition visitors with new tabletting technologies

28 Jun 2018

Company's Wear Indicator Layer attracts the most attention.

Read more